PharmaDeals Review Business Commentaries
Dr Fintan Walton, PharmaVentures’ CEO, provides monthly comment on topical biotechnology and pharmaceutical industry issues. Includes access to Fintan’s commentaries broadcast on PharmaTelevision.
Available as PDF
(Subscribers only)
The Supreme Court Changes Biotech Deal Flow
From issue 62 of the PharmaDeals Review (2005-08-01)
In the recent case of Integra LifeSciences vs. Merck KGaA, the US Supreme Court has provided a broad exemption to patent infringement that could change the way that biotech deals are done: companies can now develop both generic and new drugs free from infringement. This feature discusses the negotiation of deals in light of the decision.
Available as PDF
(Subscribers only)
Therapy Focus: Acute Myeloid Leukaemia
From issue 62 of the PharmaDeals Review (2005-08-01)
Of the four main types of leukaemia, AML is the most common. We look here at the major challenges that companies involved in AML therapy research face, and some alternative treatment options that are under investigation. All are vying for a place in what is undoubtedly a niche market.
Available as PDF
(Subscribers only)
Serono Continues its Deal Making Spree through Collaborations with BioMarin and NovImmune
From issue 61 of the PharmaDeals Review (2005-07-01)
Within the space of 2 days in May 2005, Serono has announced valuable agreements with BioMarin Pharmaceutical and NovImmune, respectively. For Serono these are the latest in an expensive deal making spree. This feature considers the impact of the alliances for all three partners.
Available as PDF
(Subscribers only)
Anadys Lands Lucrative HCV Deal with Novartis
From issue 61 of the PharmaDeals Review (2005-07-01)
Anadys Pharmaceuticals has secured Novartis as a global co-development, and potentially co-promotion, partner for ANA975, its promising Phase I therapy for chronic HCV infections. This feature considers why this is a transforming deal for Anadys that will also stand to benefit Novartis.
Available as PDF
(Subscribers only)
Royalty Rates Used in Pharmaceutical Agreements
From issue 61 of the PharmaDeals Review (2005-07-01)
This article, which is adapted from the 2005 PharmaVentures report A Guide to Royalty Rates in Pharmaceutical Licensing Deals, presents guidelines on appropriate royalty rates for new pharmaceuticals. These draw upon a survey of pharmaceutical licensing executives undertaken in 2001. The results were, overall, consistent with PharmaVentures' experience in deal analyses and negotiations.
Last Issue PDF
RSS